drugset
drugset / Trial / NCT02957656

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

NCT02957656 ↗

Phase 1 Completed 53 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of one dose of H7N9 pandemic live attenuated influenza vaccine (H7N9 pLAIV) followed by AS03-adjuvanted H7N9 pandemic inactivated influenza vaccine (H7N9 pIIV).

Timeline

Start
2016-12
Primary completion
2018-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AS03 Other / unclassified — Intramuscular
Subject H7N9 pIIV Vaccine 15 ug Intramuscular
Subject H7N9 pIIV Vaccine 30 ug Intramuscular
Subject H7N9 pLAIV Vaccine 1e+07 unknown —

Indications

No indication recorded.